CEBPZ and acute myeloid leukemia: The data demonstrated a significant impact of high-dose cytarabine on long-term remission in the CBF and normal karyotype AML groups, whereas patients with other cytogenetic alterations showed an uncertain outcome, irrespective of cytarabine dose and schedule (54).